OncoSec Medical Inc (ONCSQ)
OncoSec Medical Inc. is a healthcare company whose common stock is quoted on OTC Markets under the symbol ONCS.Q. The company focused on late-stage immuno-oncology and the development of intra-tumoral DNA-based therapeutics designed to enhance anti-tumor immune responses in cancer treatment. Its pipeline included programs such as KEYNOTE-695 for advanced melanoma, TAVO-based combinations across indications including COVID-19, squamous cell carcinoma of the head and neck, breast cancer, solid tumors, and metastatic melanoma, as well as OMS-100 and OMS-102. OncoSec also reported research and clinical collaborations with Merck & Co., its subsidiary, and Duke University’s Center for Applied Therapeutics. The company was previously known as NetVentory Solutions Inc., adopted its current name in 2011, and was incorporated in 2008. It was headquartered in Pennington, New Jersey, and filed a voluntary Chapter 7 liquidation petition in June 2023.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Market Cap |
|---|---|---|---|---|---|---|
|
OTC-ONCS.Q
|
Not available
|
Not available
|
Not available
|
Weak
|
0.0%
|
0.005 K
|
